Mitochondria are the powerhouses of our cells, playing a critical role in metabolism, signaling, apoptosis (programmed cell death), and immune function. Once thought of as simple power generators, mitochondria are now recognized as dynamic regulators of cellular health and disease, and serve as critical signaling hubs. Mitochondrial dysfunction has been linked to a wide range of disorders—including neurodegeneration, metabolic disease, cancer, and rare genetic syndromes.

Mitochondria are a key node in the body’s normal function. Despite their importance, the therapeutic potential of mitochondrial biology remains largely untapped. At BPGbio, we are changing that.

With decades of pioneering research in mitochondrial science, BPGbio is at the forefront of developing precision therapies that address some of the most difficult diseases of our time.

Our proprietary AI-driven NAi Interrogative Biology ® Platform, which is built to use Bayesian methodologies for systems-level analysis, (not just isolated organs or pathways) — integrates multiomics data, disease networks, and patient-derived signals to decode disease mechanisms at unprecedented depth.

By integrating multi-omics data with real-world biospecimens, we are able to identify mitochondrial dysfunction as a common driver across diverse indications—and develop targeted therapies to address it.

This approach has led to the development of BPM31510, our lead clinical-stage asset that directly targets mitochondrial metabolism in cancer and other rare diseases.

BPGbio’s BPM31510 is a drug-lipid conjugate nanodispersion comprised of oxidized Coenzyme Q10 (CoQ10).

Apart from being a potential candidate for mitochondrial diseases and wound healing, which involves mitochondrial metabolism, BPM31510 is also a first in class molecule that specifically targets the dysregulated metabolism observed in cancer, while supporting efficient metabolism of non-tumorigenic tissue.

Mitochondrial metabolism is altered in cancers cells, which helps support uncontrolled growth. By utilizing BPM3150 to target mitochondrial metabolism in cancer cells, we are able reengage the mitochondrial machinery to induced reactive species damage specifically in cancer leading to cancer cell death while protecting normal cells.

BPM31510 GBM: https://bpgbio.com/clinical-trials/glioblastoma-multiforme-gbm/

BPM31510 Pancreatic Cancer: https://bpgbio.com/clinical-trials/pancreatic-cancer/

BPM31510 Primary CoQ10 Deficiency: https://bpgbio.com/primary-coq10-deficiency/

BPM31510 EB: https://bpgbio.com/clinical-trials/epidermolysis-bullosa-eb/

BPM31510 Sarcopenia: https://bpgbio.com/clinical-trials/sarcopenia/